• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy.

作者信息

Kimura Ayaka, Takeda Ayaka, Ikebukuro Toyo, Hori Junko

机构信息

Department of Ophthalmology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1, Nagayama, Tama, Tokyo, 206-8512, Japan.

Department of Ophthalmology, Nippon Medical School Hospital, 1-1-5, Sendagi, Bunkyo, Tokyo, 113-8603, Japan.

出版信息

J Ophthalmic Inflamm Infect. 2021 Feb 15;11(1):3. doi: 10.1186/s12348-020-00234-y.

DOI:10.1186/s12348-020-00234-y
PMID:33586015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7882645/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/7882645/79100469ba0b/12348_2020_234_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/7882645/d604eed16c69/12348_2020_234_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/7882645/79100469ba0b/12348_2020_234_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/7882645/d604eed16c69/12348_2020_234_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2359/7882645/79100469ba0b/12348_2020_234_Fig2_HTML.jpg

相似文献

1
Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy.度普利尤单抗治疗后与过敏性结膜炎相关的血清IgE降低及反常嗜酸性粒细胞增多
J Ophthalmic Inflamm Infect. 2021 Feb 15;11(1):3. doi: 10.1186/s12348-020-00234-y.
2
Expression of ICAM-1 on conjunctival epithelium and ECP in tears and serum from children with allergic conjunctivitis.过敏性结膜炎患儿结膜上皮细胞中ICAM-1的表达以及泪液和血清中的嗜酸性粒细胞阳离子蛋白
Ann Allergy Asthma Immunol. 1999 Jun;82(6):579-85. doi: 10.1016/S1081-1206(10)63170-5.
3
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.度普利尤单抗治疗真实世界中法国多中心成人队列特应性皮炎的疗效和安全性。
J Am Acad Dermatol. 2019 Jul;81(1):143-151. doi: 10.1016/j.jaad.2019.02.053. Epub 2019 Feb 27.
4
Relationship between total tear IgE and specific serum IgE in autumnal allergic conjunctivitis.秋季变应性结膜炎患者总 IgE 与特异性 IgE 的关系。
Cornea. 2013 Jan;32(1):14-9. doi: 10.1097/ICO.0b013e318253214b.
5
Local allergic conjunctivitis: a phenotype of allergic conjunctivitis.局部过敏性结膜炎：过敏性结膜炎的一种表型。
Int Ophthalmol. 2019 Nov;39(11):2539-2544. doi: 10.1007/s10792-019-01101-z. Epub 2019 May 15.
6
Relationship between myopia and allergen-specific serum IgE levels in patients with allergic conjunctivitis.过敏性结膜炎患者近视与变应原特异性血清IgE水平之间的关系。
Clin Exp Ophthalmol. 2009 Sep;37(7):670-7. doi: 10.1111/j.1442-9071.2009.02130.x.
7
Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.特应性皮炎患者在接受和未接受度普利尤单抗治疗时的结膜炎情况——国际特应性皮炎理事会的调查和意见。
J Eur Acad Dermatol Venereol. 2019 Jul;33(7):1224-1231. doi: 10.1111/jdv.15608. Epub 2019 May 6.
8
Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?2017 年批准用于治疗特应性皮炎后dupilumab 的新进展：有哪些新进展和下一步计划？
Curr Opin Allergy Clin Immunol. 2019 Aug;19(4):341-349. doi: 10.1097/ACI.0000000000000551.
9
Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.特应性皮炎患者接受度普利尤单抗治疗相关结膜炎的风险因素。
JAMA Dermatol. 2018 Oct 1;154(10):1208-1211. doi: 10.1001/jamadermatol.2018.2690.
10
Correlations between allergen-specific IgE serum levels in patients with allergic conjunctivitis in spring.春季过敏性结膜炎患者血清中变应原特异性IgE水平的相关性。
Ocul Immunol Inflamm. 2004 Mar;12(1):45-51. doi: 10.1076/ocii.12.1.45.28067.

引用本文的文献

1
[Diagnosis and drug therapy of chronic rhinosinusitis].[慢性鼻-鼻窦炎的诊断与药物治疗]
HNO. 2025 Apr 16. doi: 10.1007/s00106-025-01635-y.
2
Temporal trends of blood eosinophilia in severe uncontrolled CRSwNP treated with dupilumab: a real-life study.在接受度普利尤单抗治疗的严重未控制的 CRSwNP 患者中血液嗜酸性粒细胞增多的时间趋势：一项真实世界研究。
Eur Arch Otorhinolaryngol. 2024 May;281(5):2429-2440. doi: 10.1007/s00405-023-08417-8. Epub 2023 Dec 29.
3
Atopic dermatitis and ocular allergy: common mechanisms and uncommon questions.特应性皮炎和眼部过敏：共同的机制和不常见的问题。

本文引用的文献

1
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.真实世界中评估度普利尤单抗疗效和不良事件风险的证据：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.
2
Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series.接受度匹鲁单抗治疗的特应性皮炎患者出现反常性头颈部红斑的临床和组织病理学特征：病例系列研究。
Br J Dermatol. 2020 Oct;183(4):745-749. doi: 10.1111/bjd.18730. Epub 2019 Dec 22.
3
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
Curr Opin Allergy Clin Immunol. 2023 Oct 1;23(5):383-389. doi: 10.1097/ACI.0000000000000931. Epub 2023 Jul 28.
4
Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.度普利尤单抗与结膜炎之间的关联：一项对随机对照试验的系统评价和荟萃分析
Pharmaceutics. 2023 Mar 23;15(4):1031. doi: 10.3390/pharmaceutics15041031.
5
Cellular mechanisms and effects of IL-4 receptor blockade in experimental conjunctivitis evoked by skin inflammation.皮肤炎症诱发实验性结膜炎中 IL-4 受体阻断的细胞机制和作用。
JCI Insight. 2023 Feb 8;8(3):e163495. doi: 10.1172/jci.insight.163495.
6
Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescribers in the Australian setting.度普利尤单抗相关的眼表疾病：澳大利亚环境下处方者的跨学科决策框架。
Australas J Dermatol. 2022 Nov;63(4):421-436. doi: 10.1111/ajd.13924. Epub 2022 Sep 20.
7
Short communication: Comments on hair disorders associated with dupilumab based on VigiBase.短篇通讯：基于 VigiBase 的有关度普利尤单抗相关毛发疾病的评论。
PLoS One. 2022 Jul 27;17(7):e0270906. doi: 10.1371/journal.pone.0270906. eCollection 2022.
8
Comment on: 'Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae'.关于《度普利尤单抗相关的眼表疾病：表现、管理及长期后遗症》的评论
Eye (Lond). 2022 Jul;36(7):1515. doi: 10.1038/s41433-021-01779-5. Epub 2021 Sep 30.
9
Immunopharmacology in Vernal Keratoconjunctivitis: Current and Future Perspectives.春季角结膜炎的免疫药理学：现状与未来展望
Pharmaceuticals (Basel). 2021 Jul 9;14(7):658. doi: 10.3390/ph14070658.
度普利尤单抗治疗中重度特应性皮炎的实验室安全性：三项III期试验（LIBERTY AD SOLO 1、LIBERTY AD SOLO 2、LIBERTY AD CHRONOS）的结果
Br J Dermatol. 2020 May;182(5):1120-1135. doi: 10.1111/bjd.18434. Epub 2019 Dec 1.
4
Conjunctivitis in dupilumab clinical trials.临床试验中的结膜炎。
Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7.
5
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.度普利尤单抗在中重度未控制哮喘中的疗效和安全性。
N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.
6
Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis.特应性皮炎成人患者中某些眼部疾病的发病率、患病率和风险。
J Am Acad Dermatol. 2017 Aug;77(2):280-286.e1. doi: 10.1016/j.jaad.2017.03.003.
7
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.两项度普利尤单抗治疗特应性皮炎的 3 期临床试验。
N Engl J Med. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30.
8
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial.皮下注射度普利尤单抗对慢性鼻-鼻窦炎伴鼻息肉患者鼻息肉负担的影响：一项随机临床试验。
JAMA. 2016 Feb 2;315(5):469-79. doi: 10.1001/jama.2015.19330.
9
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.度普利尤单抗治疗外用药物治疗控制不佳的中重度特应性皮炎成人患者的疗效和安全性：一项随机、安慰剂对照、剂量范围的 2b 期临床试验。
Lancet. 2016 Jan 2;387(10013):40-52. doi: 10.1016/S0140-6736(15)00388-8. Epub 2015 Oct 8.
10
Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.度普利尤单抗治疗中重度特应性皮炎成人患者。
N Engl J Med. 2014 Jul 10;371(2):130-9. doi: 10.1056/NEJMoa1314768.